Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study.

ABSTRACT:

Background/objectives

This study reported real-world visual acuity (VA), treatment patterns, and ocular safety outcomes from patients with macular oedema secondary to branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO) treated with anti-vascular endothelial growth factor (VEGF).

Methods

Data were collected from Medisoft electronic medical records across 16 NHS ophthalmology sites in England over 60 months.

Results

3511/3465 eyes/patients with BRVO and 3568/3514 eyes/patients with CRVO or HRVO were included; <2% of patients had bilateral RVO and had both eyes included. VA change from index anti-VEGF treatment was lower with longer follow-up. In BRVO eyes, mean (95% CI) change in VA from index was +11.2 (10.6, 11.7) approximate Early Treatment Diabetic Re

SUBMITTER: Dinah C 

PROVIDER: S-EPMC12764885 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature